Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Silverman

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Ophthalmology. Retina|March 23, 2020
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 TrialsJeffrey S Heier, Dante Pieramici, Usha Chakravarthy, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Ophthalmology Science|October 17, 2022
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and RationaleNicole Eter, Rishi P Singh, Francis Abreu, et al.
JAMA Network Open|November 29, 2022
Findings From Severe Maternal Morbidity Surveillance and Review in MarylandCarrie Wolfson, Jiage Qian, Pamela Chin, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsCharles C Wykoff, Francis Abreu, Anthony P Adamis, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsJeffrey S Heier, Arshad M Khanani, Carlos Quezada Ruiz, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Ophthalmology|December 29, 2023
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE TrialsTien Y Wong, Zdenka Haskova, Kemal Asik, et al.
American Journal of Obstetrics & Gynecology MFM|January 4, 2025
Severe maternal morbidity contributed by obstetric hemorrhage: Maryland, 2020-2022Carrie Wolfson, Jessica Tsipe Angelson, Robert Atlas, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Ophthalmology. Retina|March 23, 2020
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 TrialsJeffrey S Heier, Dante Pieramici, Usha Chakravarthy, et al.
JAMA Ophthalmology|April 9, 2026
Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical TrialSumit Sharma, Phoebe Lin, Allen Hu, et al.
Ophthalmology Science|October 17, 2022
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and RationaleNicole Eter, Rishi P Singh, Francis Abreu, et al.
JAMA Network Open|November 29, 2022
Findings From Severe Maternal Morbidity Surveillance and Review in MarylandCarrie Wolfson, Jiage Qian, Pamela Chin, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsCharles C Wykoff, Francis Abreu, Anthony P Adamis, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsJeffrey S Heier, Arshad M Khanani, Carlos Quezada Ruiz, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Ophthalmology|December 29, 2023
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE TrialsTien Y Wong, Zdenka Haskova, Kemal Asik, et al.
American Journal of Obstetrics & Gynecology MFM|January 4, 2025
Severe maternal morbidity contributed by obstetric hemorrhage: Maryland, 2020-2022Carrie Wolfson, Jessica Tsipe Angelson, Robert Atlas, et al.
Pageof 5